Iterion Therapeutics is a clinical-stage, biopharmaceutical company dedicated to revolutionizing healthcare through novel drug discovery and innovation.

At Iterion Therapeutics, we’re developing novel therapeutics for cancer. Our lead product, tegavivint, is a first-in-class, small molecule inhibitor of Transducin Beta-like Protein 1 (TBL1), a novel downstream target of the canonical Wnt/beta-catenin signaling pathway.

Tegavivint provides a differentiated mechanism to inhibit nuclear beta-catenin, a protein implicated in multiple types of cancers accounting for over 400,000 new cases each year. TBL1 binding to nuclear beta-catenin protects nuclear beta-catenin from degradation and is necessary for oncogenic gene expression. Tegavivint binds to TBL1 in the nucleus, displacing beta-catenin and preventing beta-catenin to TBL1 binding. Free nuclear beta-catenin is then degraded, inhibiting downstream oncogenic gene transcription.

Iterion is enrolling a company-sponsored clinical trial in hepatocellular carcinoma, an indication where ~40% of patients harbor a Wnt/beta-catenin mutation and there is significant unmet clinical need. Iterion has already established tegavivint safety, pharmacodynamic, and clinical activity in a completed Phase 1 clinical trial.

The company also has deep collaborative relationships with leading institutions studying tegavivint in complementary investigator-sponsored trials.